CO-SPONSORS:

ASCO

ASTRO

IASLC

UofC

Symposium Supporters

The 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology is supported by:

BMS

Genentech

Lilly

  • Amgen
  • Astellas
  • Boehringer Ingelheim Pharmaceuticals
  • Pfizer

Industry Partners

PLATINUM:

Celgene

Genentech

SILVER:

Pfizer

BRONZE:

Boehringer Ingelheim Pharmaceuticals

Keep on top of daily events with the Daily Update

Program Agenda

Current as of May 21, 2012.

Wednesday, September 5, 2012
3:00 p.m. - 6:00 p.m. Registration
Thursday, September 6, 2012
7:00 a.m. - 5:00 p.m. Registration
7:00 a.m. - 8:00 a.m. Continental Breakfast in the Exhibit Hall
7:45 a.m. - 8:00 a.m. Welcome
Stephen M. Hahn, MD, Steering Chairman, The University of Pennsylvania, Philadelphia
8:00 a.m. - 10:00 a.m.

General Session I: Treatment of Advanced Non-small Cell Lung Cancer

Moderator(s):
Karen Kelly, MD, Program Chairman-elect, University of California Davis Comprehensive Cancer Center, Sacramento, Calif.

Speakers:

  • Advances in First-line Chemotherapy for Non-small Cell Lung Cancer
    Joan Schiller, MD, University of Texas Southwestern Medical Center, Dallas
  • Targeted Therapy Instead of Chemotherapy as First-line Systemic Treatment for Advanced Non-small Cell Lung Cancer
    James Chih-Hsin Yang, MD, National Taiwan University College of Medicine, Taipei, Taiwan
  • Which Maintenance Therapy Should I Offer My Patient?
    Silvia Novello, MD, PhD, University of Torino San Luigi Gonzaga Hospital, Orbassano, Italy
  • Role of Local Therapy in Management of Oligometastases
    Brian Kavanagh, MD, PhD, University of Colorado, Aurora, Colo.
  • When Should We Introduce Palliative Care into the Treatment of Advanced Non-small Cell Lung Cancer?
    Jennifer S. Temel, MD, Massachusetts General Hospital, Boston
10:00 a.m. - 10:30 a.m. Break in the Exhibit Hall
10:30 a.m. - 11:00 a.m. General Session II: Keynote I - The Role of the Pathologist in the Treatment of Non-small Cell Lung Cancer in 2012

Moderator(s):
Fred R. Hirsch, MD, PhD, University of Colorado Cancer Center, Aurora, Colo.

Speaker:
Ignacio I. Wistuba, MD, MD Anderson Cancer Center, Houston
11:00 a.m. - 12:30 p.m.

General Session III: Novel Therapies and Therapeutic Targets in Non-small Cell Lung Cancer

Moderator(s):
Paul A. Bunn Jr., MD, University of Colorado Denver, Aurora, Colo.

Speakers:

12:30 p.m. - 1:30 p.m. Lunch in the Exhibit Hall
1:30 p.m. - 2:30 p.m.

Breakout Session I (Concurrent): Challenges in Early-stage Non-small Cell Lung Cancer

Moderator(s):
Kemp H. Kernstine, MD, PhD, University of Texas Southwestern, Dallas

Speakers:

  • Case Presentation on Early-stage Patients
    Wilfried Eberhardt, MD, University of Essen Medical School, Essen, Germany
  • Surgery for CT Detected Non-small Cell Lung Cancer
    Masahiro Tsuboi, MD, PhD, Yokohama City University Medical Center, Yokohama, Japan
  • Appropriate Mediastinal Staging: PET vs. Mediastinoscopy vs. EBUS
    Mark K. Ferguson, MD, The University of Chicago Medical Center, Chicago
  • Adjuvant Therapy in the Molecular Era
    Mark G. Kris, MD, Memorial Sloan-Kettering Cancer Center, New York

Breakout Session II (Concurrent):
Optimal Therapy for Cord Compression

Moderator(s):
Andrea Bezjak, MD, Princess Margaret Hospital, Toronto, Ontario, Canada

Speakers:

  • Case Presentation on Cord Compression
    Kristin A. Higgins, MD, Emory University Hospital, Atlanta
  • When Should Surgery be Used for Cord Compression?
    Mark H. Bilsky, MD, Memorial Sloan-Kettering Cancer Center, New York
  • Role of Radiation Therapy in the Treatment of Cord Compression
    Yoshiya Yamada, MD, Memorial Sloan-Kettering Cancer Center, New York
  • The Role of Kyphoplasty in Treating Cord Compression
    Roger Smith, MD, Toronto Western Hospital, Toronto, Ontario, Canada
2:30 p.m. - 3:00 p.m. Break in the Exhibit Hall
3:00 p.m. - 5:00 p.m.

Oral Abstract Session I

Moderator(s):
Kathy Albain, MD, Loyola University, Maywood, Ill.
Benjamin Movsas, MD, Henry Ford Hospital, Detroit

Discussant(s):
Fadlo R. Khuri, MD, Winship Cancer Institute, Atlanta
John V. Heymach, MD, PhD, MD Anderson Cancer Center, Houston
5:00 p.m. - 6:30 p.m. Poster Session and Reception in the Exhibit Hall
5:30 p.m. - 6:30 p.m.

Poster Discussion

Moderator(s):
Masahiro Hiraoka, MD, PhD, Kyoto University, Kyoto, Japan
Jyoti D. Patel, MD, Northwestern University, Chicago

Discussant(s):
Robert D. Timmerman, MD, UT Southwestern Medical Center, Dallas
Karen Kelly, MD, Program Chairman-elect, University of California Davis Comprehensive Cancer Center, Sacramento, Calif.
Sai-Hong Ignatius Ou, MD, PhD, University of California Irvine Medical Center, Orange, Calif.

5:30 p.m. - 5:50 p.m.
Discussant
Robert D. Timmerman

5:50 p.m. - 6:10 p.m.
Discussant
Karen Kelly

6:10 p.m. - 6:30 p.m.
Discussant
Sai-Hong Ignatius Ou
Friday, September 7, 2012
7:00 a.m. - 5:00 p.m. Registration
7:00 a.m. - 8:00 a.m. Continental Breakfast in the Exhibit Hall
7:50 a.m. - 8:00 a.m. Welcome
Pasi A. Jänne, MD, PhD, Program Chairman, Dana-Farber Cancer Institute, Boston
8:00 a.m. - 9:30 a.m.

General Session IV: Lung Cancer Genomics in the Clinic

Moderator(s):
Lecia V. Sequist, MD, Massachusetts General Hospital, Boston

Speakers:

  • Current and Evolving Methods of Genotyping
    Marc Ladanyi, MD, Memorial Sloan-Kettering Cancer Center, New York
  • Guidelines for Genomic Testing in 2012
    Neal I. Lindeman, MD, Harvard Medical School, Boston
  • Cost of Routine Genotyping – Can We Afford It?
    Natasha B. Leighl, BSc, MD, MSc, Princess Margaret Hospital, Toronto, Ontario, Canada
  • The Potential Impact of Large-scale Genomic Testing on Cancer Patients and Providers
    Stacy W. Gray, MD, AM, Harvard Medical School, Boston
9:30 a.m. - 10:00 a.m. Break in the Exhibit Hall
10:00 a.m. - 10:30 a.m. General Session V: Keynote II - Evolution of Novel Radiation Strategies to Improve Therapeutic Index

Moderator(s):
Laurie E. Gaspar, MD, MBA, FACR, FASTRO, University of Colorado Denver, Aurora, Colo.

Speaker:
Lawrence B. Marks, MD, FASTRO, University of North Carolina, Chapel Hill, N.C.
10:30 a.m. - 11:30 a.m.

General Session VI: Lung Cancer Screening – One Year Later - Where Are We?

Moderator(s):
James R. Jett, MD, National Jewish Health, Denver

Speakers:
11:30 a.m. - 12:30 p.m. Lunch in the Exhibit Hall Fellows/Residents Networking Lunch
12:30 p.m. - 2:40 p.m.

Plenary Session

Moderator(s):
Pasi A. Jänne, MD, PhD, Program, Chairman Dana-Farber Cancer Institute, Boston
Fadlo R. Khuri, MD, Winship Cancer Institute, Atlanta

Discussant(s):
Corey J. Langer, MD, University of Pennsylvania, Philadelphia
Hak Choy, MD, UT Southwestern Medical Center, Dallas

  • WITHDRAWN
2:40 p.m. - 3:00 p.m. Break in the Exhibit Hall
3:00 p.m. - 4:00 p.m.

Breakout Session III (Concurrent): Malignant Mesothelioma

Moderator(s):
Kenneth Rosenzweig, MD, Mount Sinai School of Medicine, New York

Speakers:

  • Case Presentation on Mesothelioma/Introduction to MPM/ First Line Chemotherapy
    Hedy Lee Kindler, MD, The University of Chicago Medicine, Chicago
  • The Role of Lung Sparing Surgery/Surgical Options for MPM
    Joseph S. Friedberg, MD, University of Pennsylvania Health System – Presbyterian, Philadelphia
  • Radiation Therapy for MPM
    Kenneth Rosenzweig, MD, Mount Sinai School of Medicine, New York
  • Second-line Treatment for Advanced Mesothelioma – Current Standards and Ongoing Clinical Studies
    Lee M. Krug, MD, Memorial Sloan-Kettering Cancer Center, New York

Breakout Session IV (Concurrent)
Small Cell Lung Cancer and Thymoma

Moderator(s):
Ravi Salgia, MD, PhD, University of Chicago Medical Center, Chicago

Speakers:
4:00 p.m. - 4:15 p.m. Break
4:15 p.m. - 5:45 p.m.

Oral Abstract Session II

Moderator(s):
Philip D. Bonomi, MD, Rush University Medical Center, Chicago
A. Dimitrios Colevas, MD, Stanford University, Stanford, Calif.

Discussant(s):
Jeffrey A. Bogart, MD, SUNY Upstate Medical School, Syracuse, N.Y.
David R. Gandara, MD, UC Davis Comprehensive Cancer Center, Sacramento, Calif.

  • 5:35 p.m. - 5:45 p.m.
    Discussant
    David R. Gandara
Saturday, September 8, 2012
7:00 a.m. - 12:00 p.m. Registration
7:00 a.m. - 7:45 a.m. Continental Breakfast
7:40 a.m. - 7:45 a.m. Welcome
Everett E. Vokes, MD, The University of Chicago, Chicago
7:45 a.m. - 9:15 a.m.

General Session VII: Resistance to Targeted Therapies

Moderator(s):
Alex A. Adjei, MD, PhD, FACP, Roswell Park Cancer Institute, Buffalo, N.Y.

Speakers:

  • Mechanisms of Resistance
    William Pao, MD, PhD, Vanderbilt-Ingram Cancer Center, Nashville, Tenn.
  • Current Clinical Strategies to Treat TKI Resistant Cancers
    Yi-long Wu, MD, Guangdong Lung Cancer Institute, Guangzhou, China
  • Should We Continue TKIs Beyond RECIST Progression?
    Geoffrey R. Oxnard, MD, Dana-Farber Cancer Institute, Boston
  • Role of the Surgeon in Treating and Diagnosing Patients that Develop Resistance to Targeted Therapies
    Jessica S. Donington, MD, New York University Medical Center, New York
9:15 a.m. - 9:45 a.m. General Session VIII: Keynote III - How to Design Clinical Trials in Non-small Cell Lung Cancer in 2012 with Omics Data

Moderator(s):
Yu Shyr, PhD, Vanderbilt University Medical Center, Nashville, Tenn.

Speaker:
J. Jack Lee, PhD, MS, DDS, MD Anderson Cancer Center, Houston
9:45 a.m. - 10:15 a.m. Break
10:15 a.m. - 11:45 a.m.

General Session IX: Unresectable Locally-advanced Non-small Cell Lung Cancer

Moderator(s):
Wilfried Eberhardt, MD, University of Essen Medical School, Essen, Germany

Speakers:

  • Case Presentation
    Wilfried Eberhardt, MD, University of Essen Medical School, Essen, Germany
  • Novel Radiation Strategies for Stage III Non-small Cell Lung Cancer: Proton vs. IMRT vs. 3-D
    Joe Y. Chang, MD, PhD, MD Anderson Cancer Center, Houston
  • Case Presentation
    Wilfried Eberhardt, MD, University of Essen Medical School, Essen, Germany
  • Role of Radiation Dose and Fractionation in Treatment of Unresectable Stage III Non-small Cell Lung Cancer
    Jeffrey D. Bradley, MD, Washington University, St. Louis
  • Case Presentation
    Wilfried Eberhardt, MD, University of Essen Medical School, Essen, Germany
  • Integration of Targeted Therapies into Chemotherapy/Radiation
    Ramesh Rengan, MD, PhD, University of Pennsylvania Health System, Philadelphia